Survival Analysis of Palliative Radiotherapy in Patients with HER-2+ Metastatic Breast Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jan 23

PMID 38260126

Authors

Xueting Li

Xiaorong Zhong

Hongyu Xu

Jun Wang

Xianguo Liu

Yang Wang

Liang He

Jiayu Ma

Guanghua Li

Lei Liu

Affiliations

Soon will be listed here.

Abstract

Background: Whether radiotherapy can improve the long-term survival of HER-2+ metastatic breast cancer remains unclear. We launched this study to explore the effect of HER-2+ metastatic breast cancer patients through anti-HER-2 targeted therapy + radiotherapy.

Methods: 488 HER-2 + metastatic breast cancer patients who received anti-HER2 targeted ± local radiotherapy from March 2006 to September 2021 were retrospectively collected. Patients were divided into a radiotherapy group (n=207) and a non-radiotherapy group (n=281) based on whether they received radiotherapy or not. 1: 1 propensity matching analysis was used to determine two groups of patients with similar baselines.

Results: Before matching, the radiotherapy group (n=207) had a median overall survival (mOS) of 51.7 months (48.8-63.8), which was superior to the non-radiotherapy group's (n=281) mOS of 33.9 months (27.9-39.9) (P < 0.0001). Moreover, the radiotherapy group exhibited better 1-year (94.6% vs 83.9%), 3-year (70.8% vs 45.5%), and 5-year (43.3% vs 25.0%) survival rates compared to the control group. Propensity score matching analysis identified 135 pairs of baseline-matched patients. In the matched groups, the mOS was 57.2 (44.5-69.8) months in the radiotherapy group (n=135) and 34.1 (27.5-40.6) months in the non-radiotherapy group (n=135), showing a statistically significant difference (P < 0.0001). Additionally, the radiotherapy group demonstrated 1-, 3-, and 5-year survival rates of 93.2%, 71.5%, and 46.9%, respectively, while those in the non-radiotherapy group were 89.4%, 45.8%, and 22.2%, respectively. Multivariate Cox analysis revealed that the presence of brain metastasis, liver metastasis, and radiotherapy were identified as independent predictive factors significantly associated with OS.

Conclusion: In patients with HER-2 positive metastatic breast cancer, radiotherapy was associated with better survival benefits compared to those who did not receive radiotherapy.

Citing Articles

New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?.

Scandurra G, Lombardo V, Scibilia G, Sambataro D, Gebbia V, Scollo P Cancers (Basel). 2024; 16(13).

PMID: 39001528 PMC: 11240652. DOI: 10.3390/cancers16132466.

References

Hu X, Zhang J, Xu B, Cai L, Ragaz J, Wang Z . Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015; 16(4):436-46. DOI: 10.1016/S1470-2045(15)70064-1. View

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z . Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol. 2021; 39(27):3002-3011. PMC: 8445562. DOI: 10.1200/JCO.21.00163. View

Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D . Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol. 2023; 9(8):1083-1089. PMC: 10326730. DOI: 10.1001/jamaoncol.2023.1984. View

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V . Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012; (4):CD006243. PMC: 6718210. DOI: 10.1002/14651858.CD006243.pub2. View

Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos M, Zagouri F . Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Clin Breast Cancer. 2020; 21(3):e212-e219. DOI: 10.1016/j.clbc.2020.08.006. View

Strauss J, Chmura S . Oligometastatic Breast Cancer. Semin Radiat Oncol. 2022; 32(3):282-290. DOI: 10.1016/j.semradonc.2022.01.008. View

Krop I, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M . Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. J Clin Oncol. 2021; 40(5):438-448. PMC: 8824393. DOI: 10.1200/JCO.21.00896. View

Kim M . Breast Cancer Metastasis. Adv Exp Med Biol. 2021; 1187:183-204. DOI: 10.1007/978-981-32-9620-6_9. View

Strnad V, Polgar C, Ott O, Hildebrandt G, Kauer-Dorner D, Knauerhase H . Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023; 24(3):262-272. DOI: 10.1016/S1470-2045(23)00018-9. View

10.

Perez-Montero H, Lozano A, de Blas R, Sanchez J, Martinez E, Laplana M . Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness. Clin Transl Oncol. 2023; 25(6):1756-1766. DOI: 10.1007/s12094-023-03073-0. View

11.

Bartels S, Donker M, Poncet C, Sauve N, Straver M, van de Velde C . Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2022; 41(12):2159-2165. DOI: 10.1200/JCO.22.01565. View

12.

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

13.

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z . Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27(11):1904-1909. DOI: 10.1038/s41591-021-01562-9. View

14.

Su K, Gu T, Xu K, Liao H, Li X, Wen L . Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int. 2022; 16(4):858-867. PMC: 9349123. DOI: 10.1007/s12072-022-10339-2. View

15.

Costin I, Marcu L . Factors impacting on patient setup analysis and error management during breast cancer radiotherapy. Crit Rev Oncol Hematol. 2022; 178:103798. DOI: 10.1016/j.critrevonc.2022.103798. View

16.

Su K, Huang W, Li X, Xu K, Gu T, Liu Y . Evaluation of Lactate Dehydrogenase and Alkaline Phosphatase as Predictive Biomarkers in the Prognosis of Hepatocellular Carcinoma and Development of a New Nomogram. J Hepatocell Carcinoma. 2023; 10:69-79. PMC: 9850255. DOI: 10.2147/JHC.S398632. View

17.

Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Kauraniemi P . Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007; 6(7):2065-72. DOI: 10.1158/1535-7163.MCT-06-0766. View

18.

Franco P, Iorio G, Bartoncini S, Airoldi M, De Sanctis C, Castellano I . De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Med Oncol. 2018; 35(5):62. DOI: 10.1007/s12032-018-1121-8. View

19.

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi M, Moradi-Kalbolandi S . Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020; 84:106535. DOI: 10.1016/j.intimp.2020.106535. View

20.

Ibrahim H, Yaroko A . Palliative external beam radiotherapy for advanced breast cancer patients with brain metastasis in the university college hospital Ibadan. Ann Afr Med. 2019; 18(3):127-131. PMC: 6704810. DOI: 10.4103/aam.aam_42_18. View